BioNTech's ASCO Pivotal Moment: Can Pumitamig Justify the €16.8 Billion Cash Pile?

BioNTech faces critical ASCO readout for Pumitamig against Keytruda in lung cancer; shares down 16.5% monthly amid high stakes and analyst divide.

BioNTech enters one of its most consequential weeks since the pandemic peak, with Phase 2 data for its lead oncology asset Pumitamig set for release at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on 29 May. The abstracts were published on the evening of 21 May, offering an early glimpse, but the full presentation will test whether the Mainz-based company can finally convince markets that its shift from Covid-vaccine champion to credible cancer-drug developer has clinical traction.

The stakes are amplified by the fact that Pumitamig – a bispecific antibody targeting both PD-L1 and VEGF-A – is being tested head-to-head against Pembrolizumab (Keytruda) in first-line non-small cell lung cancer, as part of the ongoing ROSETTA-Lung-02 study run jointly with Bristol Myers Squibb. Keytruda sets a high bar in that indication, meaning robust data would carry outsized weight, while underwhelming results would deepen the scepticism already baked into BioNTech’s share price. The programme is a global Phase 2/3 trial, with the Phase 3 portion already recruiting; the ASCO data marks the first major public readout for the asset.

Market patience wears thin

The market has not been waiting idly. BioNTech shares closed at €78.30 on Thursday, down 16.5% on a monthly basis and trading more than 23% below their 52-week high of €101.90. The stock sits roughly 7% under its 50-day moving average and 9.5% below its 200-day average – a technical picture that underscores the underlying bearish sentiment. Analyst opinions remain sharply divided: Canaccord maintains a “Buy” rating with a $158 target, while Leerink is far more cautious at $94. In between, Bernstein SocGen Group initiated coverage on Thursday with a “Market Perform” rating and a $96 price target, implying only modest upside given the clinical uncertainties.

Bernstein’s call crystallises the central tension in the BioNTech story. The analyst highlighted the company’s formidable balance sheet – €16.76 billion in cash and securities as of 31 March, of which nearly €10 billion was pure cash – but warned that the risk of negative pivotal studies in the PD-L1/VEGF class remains high. Past failures in that category have shown no statistically significant survival benefit, and the path to approval is fraught. Bernstein’s neutral stance is not a rejection of the business model, but a signal that the pipeline must start delivering.

Financial muscle meets mounting burn

The first-quarter numbers explain why the analyst debate is not straightforwardly bearish. BioNTech posted revenue of just €118 million (down from €182.8 million a year earlier), a net loss of €532 million, and R&D spending that climbed to €557 million – all reflecting the rapid deceleration of the former Covid franchise. Yet the company still had €19.6 billion in liquidity at the end of March (dollar-denominated), and has authorised a new share buyback programme of up to $1.0 billion, valid until May 2027. That dual capacity to fund both expensive pipeline development and shareholder returns sets BioNTech apart from weaker peers.

But as Bernstein notes, a strong balance sheet cannot substitute for clinical proof. The company expects seven late-stage oncology data points this year and aims to have 15 Phase 3 trials running by year-end. Beyond Pumitamig, key readouts due in 2026 include the DYNASTY-Breast02 Phase 3 study of Trastuzumab-Pamirtecan in HR-positive, HER2-low metastatic breast cancer, and the FERN-EC-01 Phase 3 trial in HER2-positive endometrial carcinoma. Both programmes are event-driven, with data still anticipated within the calendar year.

Competition tightens in real time

BioNTech is not alone in the bispecific PD-L1/VEGF-A space. At ASCO, new data are also expected from a candidate developed by the partnership between Pfizer and 3SBio, creating direct comparators in real time. For BioNTech, the question is not just whether Pumitamig works, but how its efficacy, safety, and combinability with standard therapies stack up against those rivals. The asset is also being tested across multiple other solid tumours – hepatocellular carcinoma (first-line), glioblastoma (second-line), pancreatic cancer (first-line), and renal cell carcinoma (first-line) – in various early- to mid-stage trials, both as monotherapy and in combination.

Management has guided for full-year revenue of $2.3 billion to $2.6 billion, but the share price will hinge far more on clinical headlines than on financial forecasts in the near term. After the Chicago meeting, the next scheduled catalyst is the second-quarter earnings report. Until then, the lung cancer data from Pumitamig will set the tone – and determine whether BioNTech’s €16.8 billion fortress can buy the time the pipeline needs, or merely masks the risks that are about to be laid bare.